NIH Licenses Custom T-Cells to Hunt Down AML
Published Date: 7/24/2026
Notice
Summary
The government has developed special T cell receptors that can target a tough type of blood cancer called acute myeloid leukemia (AML), especially in patients with a specific genetic marker. These new receptors promise safer, more precise treatment with fewer side effects than current options. Researchers and companies can now license this invention to help bring this exciting therapy to patients faster.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
NCI Offers License for AML TCRs
The National Cancer Institute (NCI) is seeking research co-development partners or licensees for two T cell receptors, TCR6 and TCR7, that target mutant NPM1 in acute myeloid leukemia. The technology is listed under NIH Reference Number E-200-2025-0 and a U.S. provisional patent application (63/908,266) was filed October 30, 2025.
Targeted Therapy Opportunity for AML
These TCRs (TCR6 and TCR7) recognize the neoepitope AVEEVSLRK derived from mutant NPM1 when presented by HLA-A*11:01 and showed robust, specific killing of AML cell lines and patient-derived samples with no detected cross-reactivity to normal blood cells in pre-clinical testing. This represents a potential adoptive T cell therapy option for acute myeloid leukemia patients who have the NPM1 mutation and HLA-A*11:01, and the development stage is listed as Pre-clinical (in vivo validation).
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-18191, Submission for OMB Review; 30-Day Comment Request Data and Specimen Hub (DASH) (Eunice Kennedy Shriver National Institute of Child Health and Human Development)
The National Institutes of Health (NIH) is asking for public feedback on their Data and Specimen Hub (DASH), which helps researchers share important health data. This is a quick 30-day review to make sure the information collection is clear and useful. If you’re involved in health research or data sharing, your input by October 8, 2026, can help shape how DASH works without costing extra money or time.
2026-17899, Proposed Collection; 60-Day Comment Request; Assurance (Interinstitutional, Foreign, and Domestic) and Annual Report (Office of the Director)
The NIH wants your thoughts on their plan to keep track of animal research safety through yearly reports and assurances from institutions, both in the U.S. and abroad. This helps make sure labs follow the rules and protect animals, with no new costs or big changes expected. You’ve got until October 2, 2026, to share your feedback and help improve the process!
2026-17687, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review at the NIH is holding several closed virtual meetings in October 2026 to review and evaluate grant applications. These meetings protect private info and trade secrets, ensuring fair and confidential decisions. Scientists applying for grants in genetics, molecular sciences, oral health, and cancer research are the ones affected, with no direct cost changes announced.
2026-17438, Center For Scientific Review; Notice of Closed Meetings
The NIH's Center for Scientific Review is holding several closed virtual meetings in late September 2026 to review and evaluate grant applications. These meetings protect private info and trade secrets, affecting researchers applying for funding. No direct money changes are announced, but these reviews decide who gets research grants.
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
Previous / Next Documents
Previous: 2026-14980, Government Owned Invention Available for License: Pigment Epithelium-Derived Factor Peptides and Their Use for Treating Retinal Degeneration
The National Eye Institute has a cool new invention using special peptides to help protect eyes from inherited diseases like retinitis pigmentosa, which causes vision loss for over 100,000 Americans. They’re looking for partners to help develop easy-to-use eyedrops or gene therapy to slow down or stop this eye damage. This could bring hope and new treatments to many people with few options, and interested parties can start talking to the NIH now!
Next: 2026-14982, Agency Information Collection Activities; Comment Request; Approved State Ability To Benefit Process
The Department of Education wants to keep collecting info about how states check if students can benefit from federal student aid, without changing anything. This affects students and schools involved in federal aid programs and helps keep the process smooth. You’ve got until September 22, 2026, to share your thoughts—no cost changes, just a paperwork check-in!